ATHENS – Artificial Intelligence, technology developed by researchers at the American University of Utah, who collaborated with their Greek colleagues at the National Research Foundation (NRF), can provide information about the number of SARS-CoV-2 (new coronavirus) antibodies in just two minutes and with only four drops of blood.
The use of The “NanoSpot.ai” technology, on which the specific product is based, was presented at the pavillion of the General Secretariat for Research and Innovation (GSIK) at the 86th TIF and, although the product is not yet mass-marketed in Greece (it is only available on order, with the commercial network of “Uni-Pharma”as exclusive importer/distributor), it attracted strong interest from visitors.
The Greek researchers worked on the technical maturation of the product and in the clinical study stage. The first contact with the Americans, which resulted in the transfer of part of the procedures to Greece, was made in 2021 by OPTO, a subsidiary of “Athroa Innovations”, a Greek venture studio, which aims to increase investments in deep-tech groups, with intellectual property as a guideline.
According to the researchers, the test quickly and easily answers questions such as “is my vaccination still protecting me?” and “am I still immune after the illness?”, while it can help maintain a high immunity wall individually and collectively, with a painless measurement at the pharmacy one to three times a year.
At the same time, “it can also contribute to the prioritisation of citizens in terms of the order of vaccination for the fourth booster dose, based on the number of their antibodies”, the twenty-six-year-old researcher Vivi Bafiti explained to the Athens-Macedonian News Agency (ANA), pointing out that the aim of the research for the production of specific technology was the creation of a “point-of-care” test.